GHRP-2 vs GHRP-6: First-Generation GHRP Comparison | Peptide Intel Hub

GHRP-2 is a hexapeptide ghrelin-receptor agonist engineered for potent growth-hormone release, with a smaller appetite-axis effect than GHRP-6 but measurable cortisol and prolactin activity at research doses.

GHRP-6 is a hexapeptide ghrelin-receptor agonist engineered for growth-hormone release with a distinctive strong appetite-axis effect — the reference research tool for ghrelin-axis appetite-stimulation studies. It also produces cortisol and prolactin activity at research doses.

Both compounds act at the GHS-R1a receptor. GHRP-2 has stronger GH-release potency per dose than GHRP-6, while GHRP-6 has the stronger appetite-axis signal — the two off-target profiles are the practical differentiators in research design.

Both compounds are less selective than ipamorelin, which is why modern growth-hormone-axis research protocols favour ipamorelin as the standard GHRP arm unless the older-generation pharmacology is specifically part of the experimental design.

Both compounds have short native pharmacokinetic half-lives and are used at once- to three-times-daily research cadences in published preclinical protocols.

The similar pharmacokinetic profiles make direct GHRP-2 vs GHRP-6 comparator studies clean — the differences that emerge are receptor-selectivity and off-target-profile differences rather than cadence artefacts.

GHRP-2 is used in growth-hormone-axis research where a potent first-generation GHRP arm is needed without the strong appetite-axis signal of GHRP-6.

GHRP-6 is the standard research tool for ghrelin-axis appetite-stimulation studies, and is used in growth-hormone-axis research where the appetite-axis effect is either part of the design or an acceptable off-target.

Both GHRP-2 and GHRP-6 should only be sourced from suppliers that use independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds should be published by the supplier so a researcher can audit the analytical detail. The /trust/how-to-read-a-coa reference walks through every field on a modern COA.

Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a two-month (60-day) in-use stability window under refrigeration for both compounds.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both GHRP-2 and GHRP-6 benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose GHRP-2 when the protocol requires a potent first-generation GHRP arm without the appetite-axis confound. Researchers choose GHRP-6 when appetite-axis stimulation is central to the experimental design, or when comparator studies need both first-generation GHRPs in matched arms alongside a modern selective GHRP such as ipamorelin.

For multi-compound comparator studies, reputable suppliers can often reserve matched-batch inventory of both GHRP-2 and GHRP-6 against a project timeline so the experimental panel is sourced under a single analytical specification window.

Both Growth Hormone-Releasing Peptide-2 (GHRP-2) and Growth Hormone-Releasing Peptide-6 (GHRP-6) are synthetic, non-natural peptides that stimulate somatotrope secretion in animals and humans (PMID 9186261). These peptides operate via specific receptors located at both pituitary and hypothalamic levels (PMID 9186261). The GHRP receptor, distinct from other known G-protein-coupled receptors, has been cloned, suggesting the existence of a natural, yet undiscovered, GHRP-like ligand (PMID 9186261). The mechanisms by which GHRPs exert their effects are not fully understood, but current data suggest they may counteract somatostatinergic activity at the pituitary and/or hypothalamic levels, and potentially involve a GHRH-mediated mechanism (PMID 9186261). GHRPs can also release GH independently of hypothalamic factors GHRH and somatostatin (PMID 7920995).

GHRP-6 was the first hexapeptide extensively studied in humans, with GHRP-2 and Hexarelin being two other hexapeptides synthesized more recently for human studies (PMID 9186261). The GH-releasing activity of GHRPs is marked, dose-related, and reproducible across various administration routes, including intravenous, subcutaneous, intranasal, and even oral administration (PMID 9186261). While GHRPs show a reproducible effect, they can undergo partial desensitization, particularly with continuous infusion, though less so with intermittent administration (PMID 9186261). Prolonged administration of GHRPs has been shown to increase IGF-1 levels in both animals and humans (PMID 9186261). However, in conscious swine, GHRP-2 demonstrated higher potency but lower efficacy for GH release compared to ipamorelin and GHRP-6 (ED50 = 0.6 nmol/kg and Emax = 56+/-6 ng GH/ml plasma for GHRP-2, versus 2.3+/-0.03 nmol/kg and 65+/-0.2 ng GH/ml for ipamorelin, and 3.9+/-1.4 nmol/kg and 74+/-7ng GH/ml plasma for GHRP-6) (PMID 9849822).

A key difference between GHRP-2 and GHRP-6, and other GH secretagogues, lies in their specificity for hormone release. In conscious swine, administration of both GHRP-6 and GHRP-2 led to increased plasma levels of ACTH and cortisol (PMID 9849822). In contrast, ipamorelin, another GHRP-receptor agonist, did not release ACTH or cortisol at levels significantly different from those observed following GHRH stimulation, even at doses over 200-fold higher than its GH release ED50 (PMID 9849822). None of the GH secretagogues tested in swine, including GHRP-2 and GHRP-6, affected FSH, LH, PRL, or TSH plasma levels (PMID 9849822).

The potential for increased ACTH and cortisol suggests a broader impact on the adrenal axis for GHRP-2 and GHRP-6 compared to more selective GHRPs like ipamorelin (PMID 9849822). This difference highlights varying profiles among GHRPs regarding their effects on other endocrine pathways. In critically ill men, GHRP-2 infusion reactivated GH secretion and normalized serum IGF-I, IGFBP-3, and ALS (PMID 12030918).

Pralmorelin, also known as GHRP-2, has been studied as a diagnostic agent for Growth Hormone (GH) deficiency (PMID 15230633). Its ability to markedly increase plasma GH levels in healthy subjects, irrespective of gender, obesity, or age, forms the basis for its diagnostic use (PMID 15230633). However, in patients with GH deficiency, pralmorelin's effect on GH levels is significantly lower compared to healthy controls (PMID 15230633). A cut-off threshold of 15.0 micro g/L for the GH peak has been identified from receiver-operating characteristics curve analysis to distinguish GH-deficient patients from healthy controls (PMID 15230633). Pralmorelin (KP-102 D) was awaiting approval in Japan as a diagnostic agent for hypothalamo-pituitary function and was planned for launch in 2004 for this indication (PMID 15230633). It was also undergoing phase II clinical trials in Japan for short stature (pituitary dwarfism) as KP-102 LN, with a planned launch in 2009 (PMID 15230633).

Beyond diagnosis, GHRPs, including GHRP-2 and GHRP-6, are considered potential adjunctive therapies for managing body composition in hypogonadal males (PMID 32257855). They are described as potent stimulators of GH and IGF-1, which can significantly improve body composition by ameliorating fat gain and muscular atrophy, symptoms often associated with hypogonadism (PMID 32257855). However, current data on the clinical efficacy of GHSs, including GHRP-2 and GHRP-6, largely remain limited, indicating a need for further investigation into their role in treating men with hypogonadism (PMID 32257855).

GHRP-2, as a synthetic agonist of ghrelin, has been shown to increase food intake in humans (PMID 15699539). In a study with lean, healthy males, subcutaneous infusion of GHRP-2 (1 microg/kg/h) resulted in subjects eating 35.9 +/- 10.9% more compared to saline infusion during an ad libitum meal (PMID 15699539). This increase in food intake was observed in every subject and was comparable to the effects reported for ghrelin administration, suggesting GHRP-2 as a tool for studying ghrelin's effects on human eating behavior (PMID 15699539). As expected, serum GH levels significantly rose during GHRP-2 infusion in this human study (PMID 15699539). In goldfish, GHRP-6 mimics ghrelin-induced stimulation of food intake and suppression of locomotor activity, with 1 pmol/g body weight of GHRP-6 stimulating food intake equipotent to 10 pmol/g body weight of n-octanoyl ghrelin17 (PMID 22349352). This action of GHRP-6 in goldfish was blocked by capsaicin, suggesting mediation through capsaicin-sensitive afferents (PMID 22349352).

In pre-clinical research, GHRP-6 has been investigated for its role in metabolic regulation, particularly in the context of acute kidney injury (AKI). A self-assembling GHRP-6 peptide hydrogel was designed with the hypothesis that it could reprogram the metabolism of renal tubular epithelial cells (TECs) to enhance recovery from AKI (PMID 41327290). Metabolomic sequencing analysis in a mouse model of AKI treated with the GHRP-6 hydrogel revealed enrichment of spermidine, L-glutamine, and acetyl-CoA, which are involved in amino acid and fatty acid metabolism (PMID 41327290). Further study showed that GHRP-6 hydrogel treatment enhanced TEC survival in an ischemic microenvironment by activating the mTOR-P70 pathway, suggesting a novel therapeutic strategy for protecting TECs in AKI treatment through metabolic reprogramming (PMID 41327290).

GHRP-2 has demonstrated direct effects on myocytes, attenuating the expression of muscle-specific ubiquitin ligases. In rat soleus muscle, dexamethasone administration increased Atrogin-1 mRNA levels, which GHRP-2 significantly attenuated (PMID 18191156). GHRP-2 also decreased MuRF1 mRNA levels, irrespective of dexamethasone presence (PMID 18191156). In differentiated C2C12 myocytes (in-vitro), GHRP-2 attenuated dexamethasone-induced expression of both Atrogin-1 and MuRF1 dose-dependently and decreased the basal level of MuRF1 mRNA (PMID 18191156). This suppressive effect was blocked by [D-Lys(3)]-GHRP-6, a GHS-R1a blocker, suggesting the effect of GHRP-2 was mediated through GHS-R1a receptors in myocytes (PMID 18191156). Although IGF-I is a protective factor for muscle atrophy, GHRP-2 did not influence plasma IGF-I levels or IGF-I mRNA levels in muscles in this rat study (PMID 18191156).

GHRP-6 has shown cardioprotective properties in animal models. In a study with rats, GHRP-6 administration prevented doxorubicin-induced myocardial fibers consumption and ventricular dilation, effectively preserving left ventricular systolic function (PMID 38873418). GHRP-6 also attenuated extracardiac toxicity, preserving the integrity of epithelial organs, inhibiting interstitial fibrosis, and reducing morbidity and mortality (PMID 38873418). Mechanistically, GHRP-6 was found to sustain cellular antioxidant defense, upregulate the prosurvival gene Bcl-2, and preserve cardiomyocyte mitochondrial integrity in rats (PMID 38873418). Interestingly, [D-Lys3]-GHRP-6, which is regarded as a GHSR antagonist, enhanced autophagic signaling in both normal and doxorubicin-injured skeletal muscle, demonstrated by increases in beclin-1 and LC3 II-to-LC3 I ratio (PMID 25450862). It also reduced the activation of muscle apoptosis induced by doxorubicin (PMID 25450862). The pro-autophagic effects of [D-Lys3]-GHRP-6 were found to be abolished by co-treatment with a CXCR4 antagonist, suggesting mediation through CXCR4 (PMID 25450862).

Both GHRP-2 and GHRP-6, along with other peptidyl GH secretagogues, can be administered through various routes, including intranasal application, which appears promising for systemic delivery (PMID 9879640). In male rats, the bioavailability of GHRP-2 after intranasal application was approximately 50%, which was higher than GHRP-6, whose nasal absorption was somewhat lower (PMID 9879640). Following intravenous bolus injection in rats, plasma concentrations of these peptides declined biexponentially (PMID 9879640). Ipamorelin exhibited a systemic plasma clearance five-fold lower than GHRP-6 (PMID 9879640). While ipamorelin was primarily excreted in the urine, GHRP-6 was predominantly excreted in the bile (PMID 9879640).

Metabolism and excretion patterns differ between these peptides. In a human volunteer study after nasal administration, GHRP-2, GHRP-2 free acid, and GHRP-2 (1-3) free acid were detectable in urine for up to 47 hours (PMID 25869809). GHRP-6, however, was mostly excreted unchanged and was detectable in urine for 23 hours, with its metabolites detectable for only 12 hours (PMID 25869809). The detection window after GHRP administration depends on individual metabolism, drug preparation form, and administration route (PMID 25869809). These GHRPs are listed on the World Anti-Doping Agency (WADA) Prohibited List due to their ability to stimulate endogenous growth hormone secretion, which could generate an ergogenic effect (PMID 26811125, PMID 25869809).

The GH-releasing activity of GHRPs, including GHRP-2 and GHRP-6, is synergistic with that of Growth Hormone-Releasing Hormone (GHRH) (PMID 9186261). Studies in human subjects show that chronic administration of either GHRP-2 or GHRH can convert an additive GHRP-2 + GHRH GH response into a synergistic one (PMID 8887169). The type of synergistic response induced by chronic GHRP-2 versus GHRH was different (PMID 8887169). The extent of desensitization of the GH response during chronic administration depends partly on the dosage and frequency (PMID 8887169). In critically ill men, combined administration of GHRP-2, TRH, and GnRH evoked superior endocrine and metabolic effects compared to GHRP-2 alone, with GHRP-2 + TRH infusion reactivating both the GH and thyroid axes (PMID 12030918).

The GH-releasing effect of GHRPs does not depend on sex but shows age-related variations (PMID 9186261). It increases from birth to puberty, remains consistent in adulthood, and then decreases (PMID 9186261). By the sixth decade of life, the activity of GHRPs is reduced but remains marked and higher than that of GHRH (PMID 9186261). In bovine somatotropes (in-vitro), the combined administration of GHRP-6 with GHRH resulted in an additive effect on GH release that was significant compared to GHRH alone, but not synergistic as observed in rat pituitary cells (PMID 10494658). This suggests species-specific differences in the interaction between GHRP-6 and GHRH (PMID 10494658).

In the diagnosis of GH-deficiency, GHRP-6 has been evaluated (PMID 8887178). While the GH response to GHRP-6 was lower in children with GHD than in normal children, there was considerable overlap between the groups on an individual basis (PMID 8887178). However, an almost complete blockade of GH response to either GHRP-6 or GHRH plus GHRP-6 was observed in patients with pituitary stalk transection, suggesting its potential as a cost-effective diagnostic test for this condition (PMID 8887178). Similarly, the combined GHRH plus GHRP-6 test may be valuable in diagnosing adult-onset GHD (PMID 8887178). The GH response after GHRH is more impaired in different metabolic states than after GHRP-6, while the GH response after GHRP-6 is more impaired than after GHRH in various neuroendocrine pathologies (PMID 8887173).

• Ipamorelin, the first selective growth hormone secretagogue. — European journal of endocrinology (1998). PMID 9849822
• Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. — Drugs in R&D (2004). PMID 15230633
• Growth hormone-releasing peptides. — European journal of endocrinology (1997). PMID 9186261
• GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1. — Life sciences (2008). PMID 18191156
• Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. — The Journal of clinical endocrinology and metabolism (2005). PMID 15699539
• Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. — Translational andrology and urology (2020). PMID 32257855
• Structure-activity relationship for peptídic growth hormone secretagogues. — Drug testing and analysis (2017). PMID 26811125
• GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans. — Journal of pediatric endocrinology & metabolism : JPEM (1996). PMID 8887169
• Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. — Drug testing and analysis (2015). PMID 25869809
• The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. — Clinical endocrinology (2002). PMID 12030918
• Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency. — Journal of pediatric endocrinology & metabolism : JPEM (1996). PMID 8887178
• Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation. — Journal of nanobiotechnology (2025). PMID 41327290
• Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. — Frontiers in pharmacology (2024). PMID 38873418
• [D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle. — Molecular and cellular endocrinology (2015). PMID 25450862
• Evaluation of pituitary GH reserve with GHRP-6. — Journal of pediatric endocrinology & metabolism : JPEM (1996). PMID 8887173
• Regulation of growth hormone secretion by the growth hormone releasing hexapeptide (GHRP-6). — The Journal of pediatric endocrinology (1993). PMID 7920995
• GHRP-6 in heifer and cow adenohypophisial cells separated by elutriation. — Journal of physiology and biochemistry (1999). PMID 10494658
• GHRP-6 mimics ghrelin-induced stimulation of food intake and suppression of locomotor activity in goldfish. — Peptides (2012). PMID 22349352
• Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. — Xenobiotica; the fate of foreign compounds in biological systems (1998). PMID 9879640

Both GHRP-2 and GHRP-6 are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on Peptide Intel Hub exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.